Short Course Radiation Therapy in Palliative Treatment of Brain Metastases

Not Applicable

• Conditions: Brain Metastases; Radiotherapy; Palliative Care
• Interventions: Radiation: short course treatment; Radiation: standard treatment

• Registration Number: NCT03525301
• Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Brief Summary

Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic brain metastases from solid tumors

Detailed Description

Standard treatment for brain metastases (3000 cGy in 10 daily fractions of 300 cGy each) is compared with experimental treatment (1800 cGy in 4 fractions of 450 cGy twice a day) to demonstrate non-inferiority of this scheme

Study Timeline

• Study Start: 2017-11-08
• Status Verified: 2018-05
• Study First Submitted: 2018-05-03
• Study First Submitted QC: 2018-05-03
• Study First Posted: 2018-05-15
• Last Update Submitted: 2018-05-15
• Last Update Posted: 2018-05-18
• Primary Completion: 2022-11-08
• Study Completion: 2023-11-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

• symptomatic brain metastases from solid tumors
• age > 18 years
• ECOG performance status 0-3
• no changes in supportive care in the week before radiotherapy

Exclusion Criteria

• pregnancy
• previous irradiation of the same region

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
short course treatment	short course treatment	patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
standard treatment	standard treatment	patients in this group are treated with 3000 cGy in 10 daily fractions

Primary Outcome Measures

Name	Time	Method
Efficacy of palliation using the short course scheme compared with the standard scheme	3 months	Reduction of initial symptoms after radiotherapy, assessed with Likert scale (weakness, motor disorders, cognitive impairment, personality changes, loss of balance, seizures, changes in speech, vision, hearing, memory problems, nausea or vomiting are evaluated as none-mild-moderate-severe)

Secondary Outcome Measures

Name	Time	Method
Acute toxicity in the two treatment groups	3 months	Incidence of treatment-related acute adverse events in the two arms of the study registered using Cooperative Group Common Toxicity Criteria
Late toxicity in the two treatment groups	12 months	Incidence of treatment-related late adverse events in the two arms of the study registered using RTOG/EORTC Late Radiation Morbility Scoring Schema
Quality of Life (QoL) assessment in the two groups	12 months	Changes in QoL after the treatment assessed using European Organization for Research and Treatment of Cancer (EORTC) questionnaire C15-PAL (a specific questionnaire from EORTC developed to assess the quality of life of palliative cancer care patients)

Trial Locations

Locations (1)

Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital; 🇮🇹 Bologna, BO, Italy